Exploring different virtual screening strategies for acetylcholinesterase inhibitors

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mishra, Nibha ^a   Basu, Arijit ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; EDROPHONIUM; HUPERZINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; ACETYLCHOLINESTERASE; CHOLINESTERASE; LIGAND; MUTANT PROTEIN;

AREA UNDER THE CURVE; ARTICLE; DRUG SCREENING; MOLECULAR DOCKING; PHARMACOPHORE; RECEIVER OPERATING CHARACTERISTIC; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER INTERFACE; ENZYME ACTIVE SITE; HUMAN; METABOLISM;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTANT PROTEINS; ROC CURVE; USER-COMPUTER INTERFACE;

EID: 84889031291     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/236850     Document Type: Article

References (34)

1. Kandel E. R., Schwartz J. H., Jessell T. M., Principles of Neural Science. 1991 Norwalk, Conn, USA Appleton & Lange E. R. Kandel, Ed.
2. Moghul S., Wilkinson D., Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Review of Neurotherapeutics 2001 1 1 61 69 2-s2.0-0035741357 10.1586/14737175.1.1.61 (Pubitemid 34627369)
3. Alward W. L. M., Medical management of glaucoma. New England Journal of Medicine 1998 339 18 1298 1307 2-s2.0-0032578846 10.1056/NEJM199810293391808 (Pubitemid 28496198)
4. Lindstrom J. M., Acetylcholine receptors and myasthenia. Muscle & Nerve 2000 23 453 477 (Pubitemid 30164770)
5. Taylor P., Goodman & Gilman's the Pharmacological Basis of therapeutics 2001 J. G. Hardman, L. E. Limbird, and A. G.Gilman, Eds.
6. Guo J., Hurley M. M., Wright J. B., Lushington G. H., A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. Journal of Medicinal Chemistry 2004 47 22 5492 5500 2-s2.0-6044238257 10.1021/jm049695v (Pubitemid 39382797)
7. Mizutani M. Y., Itai A., Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. Journal of Medicinal Chemistry 2004 47 20 4818 4828 2-s2.0-4544366514 10.1021/jm030605g (Pubitemid 39238256)
8. Rollinger J. M., Hornick A., Langer T., Stuppner H., Prast H., Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. Journal of Medicinal Chemistry 2004 47 25 6248 6254 2-s2.0-9744238799 10.1021/jm049655r (Pubitemid 39587249)
9. Glide,. Schrödinger, LLC, New York, NY, USA, 2008
10. ROCS 2.3.1,. OpenEye Scientific Software, Santa Fe, NM, USA, 2007
11. EON 2.0.1.,. OpenEye Scientific Software, Santa Fe, NM, USA, 2007
12. Huang N., Shoichet B. K., Irwin J. J., Benchmarking sets for molecular docking. Journal of Medicinal Chemistry 2006 49 23 6789 6801 2-s2.0-33750991346 10.1021/jm0608356 (Pubitemid 44749746)
13. OMEGA 2.3.2,. OpenEye Scientific Software, Santa Fe, NM, USA, 2008
14. Davis I. W., Leaver-Fay A., Chen V. B., Block J. N., Kapral G. J., Wang X., Murray L. W., Arendall 3rd. W. B., Snoeyink J., Richardson J. S., Richardson D. C., MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic acids research 2007 35 W375 W383 2-s2.0-34547592557 10.1093/nar/gkm216
15. Sharma V., Pattanaik K. K., Jayprakash V., Basu A., Mishra N., A utility script for automating and integrating AutoDock and other associated programs for virtual screening. Bioinformation 2009 4 84 86 10.6026/97320630004084
16. Dixon S. L., Smondyrev A. M., Knoll E. H., Rao S. N., Shaw D. E., Friesner R. A., PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design 2006 20 10-11 647 671 2-s2.0-33845868822 10.1007/s10822-006-9087-6 (Pubitemid 46023928)
17. Dixon S. L., Smondyrev A. M., Rao S. N., PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chemical Biology and Drug Design 2006 67 5 370 372 2-s2.0-33745213575 10.1111/j.1747-0285.2006.00384.x
18. Bender A., Glen R. C., A discussion of measures of enrichment in virtual screening: Comparing the information content of descriptors with increasing levels of sophistication. Journal of Chemical Information and Modeling 2005 45 5 1369 1375 2-s2.0-26944443036 10.1021/ci0500177 (Pubitemid 41478810)
19. Lovell T., Chen H., Lyne P. D., Giordanetto F., Li J., Erratum: On evaluating molecular-docking methods for pose prediction and enrichment factors (Journal of Chemical Information and Modeling (2006) 46 (401-415)). Journal of Chemical Information and Modeling 2008 48 1 246 2-s2.0-39449123064 10.1021/ci7003169
20. Jain A. N., Nicholls A., Recommendations for evaluation of computational methods. Journal of Computer-Aided Molecular Design 2008 22 3-4 133 139 2-s2.0-41349106542 10.1007/s10822-008-9196-5
21. Stahl M., Rarey M., Detailed analysis of scoring functions for virtual screening. Journal of Medicinal Chemistry 2001 44 7 1035 1042 2-s2.0-0035966871 10.1021/jm0003992 (Pubitemid 32852130)
22. Truchon J.-F., Bayly C. I., Evaluating virtual screening methods: good and bad metrics for the "early recognition" problem. Journal of Chemical Information and Modeling 2007 47 2 488 508 2-s2.0-34247272948 10.1021/ci600426e (Pubitemid 46615951)
23. Triballeau N., Acher F., Brabet I., Pin J.-P., Bertrand H.-O., Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry 2005 48 7 2534 2547 2-s2.0-17144385534 10.1021/jm049092j (Pubitemid 40520517)
24. Bar-On P., Millard C. B., Harel M., Dvir H., Enz A., Sussman J. L., Silman I., Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002 41 11 3555 3564 2-s2.0-0037133519 10.1021/bi020016x (Pubitemid 34224667)
25. Kryger G., Silman I., Sussman J. L., Structure of acetylcholinesterase complexed with E2020 (Aricept ρ): implications for the design of new anti-Alzheimer drugs. Structure 1999 7 3 297 307 2-s2.0-0033103478 10.1016/S0969-2126(99)80040-9 (Pubitemid 29159689)
26. Dvir H., Jiang H. L., Wong D. M., Harel M., Chetrit M., He X. C., Jin G. Y., Yu G. L., Tang X. C., Silman I., Bai D. L., Sussman J. L., X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 2002 41 35 10810 10818 2-s2.0-0037015151 10.1021/bi020151+ (Pubitemid 34971058)
27. Rydberg E. H., Brumshtein B., Greenblatt H. M., Wong D. M., Shaya D., Williams L. D., Carlier P. R., Pang Y.-P., Silman I., Sussman J. L., Complexes of Alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of bis(5)-tacrine produces a dramatic rearrangement in the active-site gorge. Journal of Medicinal Chemistry 2006 49 18 5491 5500 2-s2.0-33748544640 10.1021/jm060164b (Pubitemid 44373181)
28. Tumiatti V., Andrisano V., Banzi R., Bartolini M., Minarini A., Rosini M., Melchiorre C., Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. Journal of Medicinal Chemistry 2004 47 26 6490 6498 2-s2.0-10644228563 10.1021/jm0494366 (Pubitemid 39657311)
29. Melchiorre C., Andrisano V., Bolognesi M. L., Budriesi R., Cavalli A., Cavrini V., Rosini M., Tumiatti V., Recanatini M., Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. Journal of Medicinal Chemistry 1998 41 22 4186 4189 2-s2.0-0032561371 10.1021/jm9810452 (Pubitemid 28498739)
30. Lin G., Chen G.-H., Ho H.-C., Conformationally restricted carbamate inhibitors of horse serum butyrylcholinesterase. Bioorganic and Medicinal Chemistry Letters 1998 8 19 2747 2750 2-s2.0-0032491246 10.1016/S0960-894X(98) 00484-3 (Pubitemid 28496664)
31. Tasso B., Catto M., Nicolotti O., Novelli F., Tonelli M., Giangreco I., Pisani L., Sparatore A., Boido V., Carotti A., Sparatore F., Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. European Journal of Medicinal Chemistry 2011 46 6 2170 2184 2-s2.0-79955606915 10.1016/j.ejmech. 2011.02.071
32. Luo W., Yu Q.-S., Kulkarni S. S., Parrish D. A., Holloway H. W., Tweedie D., Shafferman A., Lahiri D. K., Brossi A., Greig N. H., Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. Journal of Medicinal Chemistry 2006 49 7 2174 2185 2-s2.0-33645687131 10.1021/jm050578p
33. Savini L., Campiani G., Gaeta A., Pellerano C., Fattorusso C., Chiasserini L., Fedorko J. M., Saxena A., Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorganic and Medicinal Chemistry Letters 2001 11 13 1779 1782 2-s2.0-0035833105 10.1016/S0960-894X(01)00294-3 (Pubitemid 32568319)
34. Bencharit S., Morton C. L., Hyatt J. L., Kuhn P., Danks M. K., Potter P. M., Redinbo M. R., Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chemistry and Biology 2003 10 4 341 349 2-s2.0-0345373886 10.1016/S1074-5521(03) 00071-1 (Pubitemid 36516652)